$178.08
-1.0%Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Chief Financial Officer & Executive Vice President
Compensation
$2,698,196
Chief Technology & AI Officer
Co-Founder & Chairman
Co-Founder & Director
Executive Officer
Compensation
$2,043,545
President, Chief Executive Officer & Director
Compensation
$5,150,421
Senior Vice President & Chief Science Officer
Compensation
$2,290,261
Senior Vice President of Human Resources
Compensation
$1,938,032
Senior Vice President, Deputy General Counsel, Secretary & Chief Sustainability Officer
Senior Vice President, General Counsel & Chief Compliance Officer
Compensation
$2,043,545
Vice President & Chief Accounting Officer
Vice President of Investor Relations
During the last 12 months, insiders have sold $36.95M worth of DHR shares, with no buying activity reported.
0
0.00
1.4K
237.21K
-237K
-$237K
0
0.00
1.3K
274.57K
-275K
-$275K
0
0.00
162.5K
35.85M
-35.8M
-$35.85M
0
0.00
2.8K
586.32K
-586K
-$586K
No buying activity
Rales Mitchell P
Director, Officer: Chairman Of Exec. Committee
$28.20M
Mcgrew Matthew
Officer: Evp & Chief Financial Officer
$3.47M
Ellis Brian W
Officer: Senior Vice President - Gc
$3.22M
List Teri
Director
$1.33M
Milosevich Gregory M
Officer: Executive Vice President
$275K
Strong bearish signal with $36.95M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
DHR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 25, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 26, 2025 | May 06, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 27, 2024 | May 07, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 29, 2023 | March 29, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 30, 2022 | May 10, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 25, 2021 | May 05, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 25, 2020 | May 05, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 27, 2019 | May 07, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 28, 2018 | May 08, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 31, 2017 | May 09, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.